SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SMS Pharmaceuticals - Quaterly Results

05 Aug 2024 Evaluate
The company witnessed a 21.51% growth in the revenue at Rs. 1644.51 millions for the quarter ended June 2024 as compared to Rs. 1353.39 millions during the year-ago period.Profit after tax for the quarter ended June 2024 reported a huge growth of 75.91% to Rs. 163.28  millions from Rs. 92.82 millions.OP of the company witnessed a marginal growth to 348.33 millions from 271.70 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202406 202306 % Var 202406 202306 % Var 202403 202303 % Var
Sales 1644.51 1353.39 21.51 1644.51 1353.39 21.51 7092.63 5220.51 35.86
Other Income 13.68 5.13 166.67 13.68 5.13 166.67 44.60 49.14 -9.24
PBIDT 348.33 271.70 28.20 348.33 271.70 28.20 1213.04 595.88 103.57
Interest 46.67 63.23 -26.19 46.67 63.23 -26.19 234.57 219.13 7.05
PBDT 301.66 208.47 44.70 301.66 208.47 44.70 978.47 376.75 159.71
Depreciation 83.82 76.91 8.98 83.82 76.91 8.98 315.16 321.25 -1.90
PBT 217.84 131.56 65.58 217.84 131.56 65.58 663.31 55.50 1095.15
TAX 54.56 38.74 40.84 54.56 38.74 40.84 169.07 14.65 1054.06
Deferred Tax 1.56 4.74 -67.09 1.56 4.74 -67.09 17.79 14.69 21.10
PAT 163.28 92.82 75.91 163.28 92.82 75.91 494.24 40.85 1109.89
Equity 84.65 84.65 0.00 84.65 84.65 0.00 84.65 84.65 0.00
PBIDTM(%) 21.18 20.08 5.51 21.18 20.08 5.51 17.10 11.41 49.84

SMS Pharmaceuticals Share Price

414.90 -5.70 (-1.36%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×